I kinda hit on that & throw in Cytodyn's low overhead cost, keeping proof of MOA cost(s) down via different ways, etc..etc.. & absolutely, the industry has a multi-faceted "problem" on their hands.

https://investorshangout.com/post/view?id=6702471

Shall see.....